Senti Biosciences Holdings, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(In thousands, except share data)
| Redeemable Convertible Preferred Stock · Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity (Deficit) | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | |||||||
| Balance at December 31, 2025 | — | $— | 30,879,355 | $3 | $364,158 | $(358,572) | $5,589 |
| Issuance of common stock for vesting of restricted stock units | — | — | 387,254 | — | — | — | — |
| Net settlement of restricted stock units for employee taxes | — | — | (121,855) | — | (118) | — | (118) |
| Stock-based compensation | — | — | — | — | 1,315 | — | 1,315 |
| Net loss | — | — | — | — | — | (4,221) | (4,221) |
| Balance at March 31, 2026 | — | — | 31,144,754 | 3 | $365,355 | (362,793) | 2,565 |
| Capital contribution from related party | — | — | — | — | 5,736 | — | 5,736 |
| Stock-based compensation | — | — | — | — | 1,048 | — | 1,048 |
| Net loss | — | — | — | — | — | (12,750) | (12,750) |
| Balance at June 30, 2026 | — | $— | 31,144,754 | $3 | $372,139 | $(375,543) | $(3,401) |
| Redeemable Convertible Preferred Stock · Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity | |||||||
| Shares · Amount · Shares · Amount | |||||||
| Balance at December 31, 2024 | 21,157 | $25,106 | 4,829,035 | $1 | $322,782 | $(297,134) | $25,649 |
| Conversion of Series A redeemable convertible preferred stock to common stock | (21,157) | (25,106) | 21,157,000 | 2 | 25,104 | — | 25,106 |
| Issuance of common stock for vesting of restricted stock units | — | — | 17,909 | — | — | — | — |
| Vesting of early exercise of common stock options | — | — | 422 | — | 12 | — | 12 |
| Stock-based compensation | — | — | — | — | 1,204 | — | 1,204 |
| Net loss | — | — | — | — | — | (14,112) | (14,112) |
| Balance at March 31, 2025 | — | — | 26,004,366 | 3 | 349,102 | (311,246) | 37,859 |
| Issuance of common stock related to ATM, net of commissions and issuance costs | — | — | 155,840 | — | — | — | — |
| Stock-based compensation | — | — | — | — | 1,526 | — | 1,526 |
| Net loss | — | — | — | — | — | (14,733) | (14,733) |
| Balance at June 30, 2025 | — | $— | 26,160,206 | $3 | $350,628 | $(325,979) | $24,652 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.